PoxelSTU:7PO -0.51%37 FCF Margin % is 347.55% as of Jun. 2025. GuruFocus rates STU:7PO with a GF Score™ of 37/100 and a GF Value™ of €1.09 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 959 Biotechnology companies, Poxel ranks better than 83.52% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Poxel's Free Cash Flow for the
six
months ended in Jun. 2025 was €7.59 Mil. Poxel's Revenue for the
six
months ended in Jun. 2025 was €2.18 Mil. Therefore, Poxel's FCF Margin % for the quarter that ended in Jun. 2025 was 347.55%.
The historical rank and industry rank for Poxel's FCF Margin % or its related term are showing as below:
STU:7PO'
s FCF Margin % Range Over the Past 10 Years
Min: -26962.86 Med: -262.91 Max: 152.93
Current: 10.66
During the past 13 years, the highest FCF Margin % of Poxel was 152.93%. The lowest was -26962.86%. And the median was -262.91%.
STU:7PO's FCF Margin % is ranked better than 83.52% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs STU:7PO: 10.66
Poxel FCF Margin % Related Terms
Poxel FCF Margin % Historical Data
* Premium members only.
The historical data trend for Poxel's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:7PO vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Poxel's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Poxel FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Poxel's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Poxel's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poxel (STU:7PO) has a FCF Margin % of 347.55% as of Jun. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Poxel and its competitors. According to the industry distribution chart, Poxel ranks #158 out of 959 companies in the Biotechnology industry, placing it in the top 16.5%.
Is Poxel's FCF Margin % too high?
Poxel's current FCF Margin % is 347.55%. Based on the distribution chart, Poxel ranks #158 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Poxel has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Poxel's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Poxel ranks #158 out of 959 companies for FCF Margin %. This places Poxel in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Poxel and its competitors. Poxel's current FCF Margin % is 347.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poxel stock overvalued right now?
Based on GuruFocus' analysis, Poxel (STU:7PO) is currently considered Possible Value Trap. The stock's GF Value™ is €1.09, compared to a current price of €0.20 — trading 82.1% below its estimated fair value. The current FCF Margin % is 347.55%. Poxel's overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Poxel (STU:7PO), the current FCF Margin % is 347.55% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Poxel (STU:7PO) Overvalued in 2026?
Based on GuruFocus' analysis, Poxel stock appears to be undervalued.
The current stock price of €0.20 is trading 82.1% below its estimated GF Value™ of €1.09.
GuruFocus considers Poxel to be Possible Value Trap.
Key valuation signals for STU:7PO:
FCF Margin %: 347.55%
GF Value™: €1.09 vs. price of €0.20 (82.1% below fair value)
No single metric tells the full story. See the STU:7PO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
37GF Score
Get the complete analysis for STU:7PO
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7PO has been successfully added to your 
